항우울제 중단 증후군

키워드

참고문헌 (81)

1. Mojtabai R, "National trends in long-term use of antidepressant medications : results from the U. S. national health and nutrition examination survey", J Clin Psychiatry, 75, pp.169~177 (2014)
2. Kim HJ, "Visual analysis of regional variations in antidepressant use and suicide rate", Korean J Clin Pharm, 28, pp.308~319 (2018)
3. Möller HJ, "Is the serotonin hypothesis", theory of depression still relevant? Methodological reflections motivated by a recently published umbrella review, 2023, pp.273, 1~3
4. Moncrieff J, "The serotonin theory of depression : a systematic umbrella review of the evidence", Mol Psychiatry, 28, pp.3243~3256 (2023)
5. [URL]
6. Baldessarini R, "The impact of psychopharmacology on contemporary psychiatry", Can J Psychiatry, 59, pp.401~405 (2014)
7. Szasz T, "The myth of mental illness" (1961), Harper & Row
8. Sakakibara E, "What is mental illness? : a defense of anti-essentialism", J Japan Assoc Philos Sci, 44, pp.55~75 (2017)
9. Li F, "Meta-analysis of placebo response in adult antidepressant trials", CNS Drugs, 33, pp.971~980 (2019)
10. Kang U, "A historical consideration of psychiatric diagnostic systems: focusing on the concept of depression", J Korean Neuropsychiatr Assoc, 53, pp.259~292 (2014)
11. Hodding GC, "Drug withdrawal syndromes : a literature review", West J Med, 133, pp.383~391 (1980)
12. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders" (2013), American Psychiatric Association
13. Leshner AI, "Addiction is a brain disease, and it matters", Science, 278, pp.45~47 (1997)
14. Tella SR, "Differential regulation of dopamine transporter after chronic self-administration of bupropion and nomifensine", J Pharmacol Exp Ther, 281, pp.508~513 (1997)
15. Haddad P, "Do antidepressants have any potential to cause addiction?", J Psychopharmacol, 13, pp.300~307 (1999)
16. National Institute for Health and Care Excellence, "Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults (NICE guideline, no. 215)", National Institute for Health and Care Excellence, ~ (2022)
17. Berwian IM, "Low predictive power of clinical features for relapse prediction after antidepressant discontinuation in a naturalistic setting", Sci Rep, 12, pp.11171~ (2022)
18. Song HR, "Antidepressants discontinuation syndrome", Korean J Psychopharmacol, 21, pp.115~123 (2010)
19. Korean Society for Affective Disorders, "Korean medication algorithm project for depressive disorder, KMAP-DD 2021" (2021), iMiS Company
20. Mann AM, "Clinical experience with imipramine(G22355)in the treatment of depression", Can Psychiatr Assoc J, 4, pp.38~47 (1959)
21. Andersen H, "Tofranil-treatment of endogenous depressions", Acta Psychiatr Scand, 34, pp.387~397 (1959)
22. Haddad PM, "Antidepressant discontinuation syndromes", Drug Saf, 24, pp.183~197 (2001)
23. Quilichini JB, "Comparative effects of 15 antidepressants on the risk of withdrawal syndrome : a real-world study using the WHO pharmacovigilance database", J Affect Disord, 297, pp.189~193 (2022)
24. Baldessarini RJ, "Illness risk following rapid versus gradual discontinuation of antidepressants", Am J Psychiatry, 167, pp.934~941 (2010)
25. Sørensen A, "Description of antidepressant withdrawal symptoms in clinical practice guidelines on depression : a systematic review", J Affect Disord, 316, pp.177~186 (2022)
26. Sadock B, "Kaplan & Sadock’s pocket handbook of psychiatric drug treatment" (2018), Wolters Kluwer
27. Benkert O, "Kompendium der psychiatrischen pharmakotherapie" (2018), Springer
28. Fava GA, "Discontinuing antidepressant medications" (2021), Oxford University Press
29. Taylor DM, "The Maudsley prescribing guidelines in psychiatry" (2021), John Wiley & Sons
30. Viguera AC, "Discontinuing antidepressant treatment in major depression", Harv Rev Psychiatry, 5, pp.293~306 (1998)
31. Duffy L, "Antidepressant medication to prevent depression relapse in primary care : the ANTLER RCT", Health Technol Assess, 25, pp.1~62 (2021)
32. Lewis G, "Maintenance or discontinuation of antidepressants in primary care", N Engl J Med, 385, pp.1257~1267 (2021)
33. Clarke CS, "Cost-utility analysis of discontinuing antidepressants in England primary care patients compared with long-term maintenance : the ANTLER study", Appl Health Econ Health Policy, 20, pp.269~282 (2022)
34. El-Mallakh RS, "Studies of long-term use of antidepressants : how should the data from them be interpreted?", CNS Drugs, 26, pp.97~109 (2012)
35. Kinrys G, "Tachyphylaxis in major depressive disorder : a review of the current state of research", J Affect Disord, 245, pp.488~497 (2019)
36. Fava GA, "May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance", Ther Adv Psychopharmacol, 10, pp.2045125320970325~ (2020)
37. Kishi T, "Relapse and its modifiers in major depressive disorder after antidepressant discontinuation : meta-analysis and meta-regression", Mol Psychiatry, 28, pp.974~976 (2023)
38. Aoki Y, "Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission", Neuropsychopharmacol Rep, 42, pp.306~314 (2022)
39. Haddad PM, "Recognising and managing antidepressant discontinuation symptoms", Adv Psychiatr Treat, 13, pp.447~457 (2007)
40. Henssler J, "Antidepressant withdrawal and rebound phenomena", Dtsch Arztebl Int, 116, pp.355~361 (2019)
41. Taylor D, "Antidepressant withdrawal symptoms-telephone calls to a national medication helpline", J Affect Disord, 95, pp.129~133 (2006)
42. Horowitz MA, "Tapering of SSRI treatment to mitigate withdrawal symptoms", Lancet Psychiatry, 6, pp.538~546 (2019)
43. Chouinard G, "Antipsychotic-induced dopamine supersensitivity psychosis : pharmacology, criteria, and therapy", Psychother Psychosom, 86, pp.189~219 (2017)
44. Hengartner MP, "Protracted withdrawal syndrome after stopping antidepressants : a descriptive quantitative analysis of consumer narratives from a large internet forum", Ther Adv Psychopharmacol, 10, pp.2045125320980573~ (2020)
45. Chouinard G, "New classification of selective serotonin reuptake inhibitor withdrawal", Psychother Psychosom, 84, pp.63~71 (2015)
46. Fava GA, "Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation : a systematic review", Psychother Psychosom, 84, pp.72~81 (2015)
47. Rosenbaum JF, "Selective serotonin reuptake inhibitor discontinuation syndrome : a randomized clinical trial", Biol Psychiatry, 44, pp.77~87 (1998)
48. Berber MJ, "FINISH : remembering the discontinuation syndrome. Flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances, and hyperarousal(anxiety", agitation), 1998, pp.59, 255~
49. Papp A, "Brain zaps : an underappreciated symptom of antidepressant discontinuation", Prim Care Companion CNS Disord, 20, pp.18m02311~ (2018)
50. Pies RW, "Antidepressant discontinuation : a tale of two narratives", J Clin Psychopharmacol, 39, pp.185~188 (2019)
51. Scholten WD, "The efficacy of a group CBT relapse prevention program for remitted anxiety disorder patients who discontinue antidepressant medication : a randomized controlled trial", Psychother Psychosom, 87, pp.240~242 (2018)
52. Narayan V, "Antidepressant discontinuation manic states : a critical review of the literature and suggested diagnostic criteria", J Psychopharmacol, 25, pp.306~313 (2011)
53. Stoukides JA, "Extrapyramidal symptoms upon discontinuation of fluoxetine", Am J Psychiatry, 148, pp.1263~ (1991)
54. Allgulander C, "Prevention of relapse in generalized anxiety disorder by escitalopram treatment", Int J Neuropsychopharmacol, 9, pp.495~505 (2006)
55. Michelson D, "Hormonal markers of stress response following interruption of selective serotonin reuptake inhibitor treatment", Psychoneuroendocrinology, 25, pp.169~177 (2000)
56. Ninan PT, "Incidence and timing of taper", posttherapy-emergent adverse events following discontinuation of desvenlafaxine 50 mg, Prim Care Companion CNS Disord, pp.2015, 17[DOI]
57. Sir A, "Randomized trial of sertraline versus venlafaxine XR in major depression : efficacy and discontinuation symptoms", J Clin Psychiatry, 66, pp.1312~1320 (2005)
58. Saxe PA, "Shortterm(2-week)effects of discontinuing milnacipran in patients with fibromyalgia", Curr Med Res Opin, 28, pp.815~821 (2012)
59. Giller E Jr, "Long-term amitriptyline in chronic depression", Hillside J Clin Psychiatry, 7, pp.16~33 (1985)
60. Gahr M, "Withdrawal and discontinuation phenomena associated with tranylcypromine : a systematic review", Pharmacopsychiatry, 46, pp.123~129 (2013)
61. Goodwin GM, "Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome : a 24-week randomized, double-blind, placebo-controlled trial", J Clin Psychiatry, 70, pp.1128~1137 (2009)
62. Holford N, "Pharmacodynamic principles and the time course of delayed and cumulative drug effects", Transl Clin Pharmacol, 26, pp.56~59 (2018)
63. Groot PC, "Successful use of tapering strips for hyperbolic reduction of antidepressant dose : a cohort study", Ther Adv Psychopharmacol, 11, pp.20451253211039327~ (2021)
64. "Taperingstrip"[URL]
65. Coleman JA, "X-ray structures and mechanism of the human serotonin transporter", Nature, 532, pp.334~339 (2016)
66. Blier P, "Physiologic mechanisms underlying the antidepressant discontinuation syndrome", J Clin Psychiatry, 67(Suppl 4), pp.8~13 (2006)
67. Gould GG, "Regulatory effects of reboxetine treatment alone, or following paroxetine treatment, on brain noradrenergic and serotonergic systems", Neuropsychopharmacology, 28, pp.1633~1641 (2003)
68. Boyer EW, "The serotonin syndrome", N Engl J Med, 352, pp.1112~1120 (2005)
69. Carvalho AF, "The safety, tolerability and risks associated with the use of newer generation antidepressant drugs : a critical review of the literature", Psychother Psychosom, 85, pp.270~288 (2016)
70. Hohagen F, "Treatment of primary insomnia with trimipramine : an alternative to benzodiazepine hypnotics?", Eur Arch Psychiatry Clin Neurosci, 244, pp.65~72 (1994)
71. "Depression in adults: treatment and management"[URL]
72. Nestoriuc Y, "Erwartungseffekte beim Absetzen von Antidepressiva. Implikationen für die Praxis", Psychotherapeut, 67, pp.213~219 (2022)
73. Bowers HM, "Supporting antidepressant discontinuation : the development and optimisation of a digital intervention for patients in UK primary care using a theory, evidence and person-based approach", BMJ Open, 10, pp.e032312~ (2020)
74. Wells RE, "To tell the truth, the whole truth, may do patients harm : the problem of the nocebo effect for informed consent", Am J Bioeth, 12, pp.22~29 (2012)
75. Phelps J, "Tapering antidepressants : is 3 months slow enough?", Med Hypotheses, 77, pp.1006~1008 (2011)
76. van Geffen EC, "Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice : tapering versus abrupt discontinuation", Eur J Clin Pharmacol, 61, pp.303~307 (2005)
77. Baldwin DS, "A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder", Int Clin Psychopharmacol, 21, pp.159~169 (2006)
78. Jefferson JW, "Strategies for switching antidepressants to achieve maximum efficacy adolescents", J Clin Psychiatry, 69(Suppl E1), pp.14~18 (2008)
79. Buckley NA, "Serotonin syndrome", BMJ, 348, pp.g1626~ (2014)
80. Benazzi F, "Fluoxetine for the treatment of SSRI discontinuation syndrome", Int J Neuropsychopharmacol, 11, pp.725~726 (2008)
81. Perahia DG, "Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants : a multicenter trial comparing 2 switching techniques", J Clin Psychiatry, 69, pp.95~105 (2008)

관련 논문AI추천